Human GPCR Panel Assay

We provide reliable and comprehensive human GPCR panel assay services on our proprietary functional assay platform (international patent filed, publication number WO/2020/026979).
Our panel services include

  • FlexPanel48, two types of focused panels with 48 GPCRs and
  • large-scale comprehensive panels covering as many as 294 GPCRs.

Listed at the bottom are the 200 non-orphan GPCRs and the 94 orphan GPCRs eligible for panel assays and the 48 GPCRs in each of the FlexPanel48 Therapeutic Area Panels. If you have any questions, feel free to ask us.


FlexPanel48 is reasonable focused panels with 48 receptors and consists of custom panels and therapeutic area panels.

Custom Panels

  • One can choose 48 receptors from the 200 non-orphan GPCRs and the 94 orphan GPCRs on our list.
  • Two assay modes, the agonist and antagonist modes, are available.
    Orphan GPCRs are assayed in the agonist mode only.
  • The two assay modes may coexist in a single panel.

FlexPanel48 Therapeutic Area Panels

13 Therapeutic Areas

  • Immunology/Infection
  • Oncology
  • Hematology
  • Endocrinology/Metabolism
  • Psychiatry
  • Neurology
  • Ophthalmology
  • Cardiology
  • Respiratory
  • Gastrointestinal
  • Dermatology
  • Musculoskeletal
  • Urology/Reproduction
  • Assorted are the 48 GPCRs with high disease-gene association scores according to the DisGeNET database.
  • The receptors in each panel are listed below.
  • Two assay modes, the agonist and antagonist modes, are available.
  • The two assay modes may coexist in a single panel.
  • One can customize a Therapeutic Area Panel by replacing receptors on the list with those of his/her choice.

Panel Assay Examples

FlexPanel48 Endocrinology/Metabolism Panel
TAK875 vs FlexPanel48 Metabol/Endocrinol

Figure 1. TAK-875 screened in the endocrinology/metabolism panel
TAK875 Concentration-response curve

Figure 2. Concentration-response curve for TAK-875

TAK-875, a Phase 3 antidiabetic, was screened in the agonist mode in the FlexPanel48 Endocrinology/Metabolism Panel (Figure 1). TAK-875 selectively activated free fatty acid receptor 1 (FFAR1). Next, TAK-875 was shown to activate FFAR1 in a concentration-dependent manner (Figure 2).

Endocrinology/Metabolism Panel Receptors
FlexPanel48 Psychiatry Panel

Figure 3. Naloxone screened in the psychiatry panel

Figure 4. Concentration-response curves for naloxone

Naloxone, the opioid reversal drug, was screened in the antagonist mode in the FlexPanel48 Psychiatry Panel (Figure 3). Naloxone selectively antagonized opiate receptors OPRD1, OPRK1, and OPRM1. Next, naloxone was shown to antagonize the three opiate receptors in a concentration-dependent manner (Figure 4).

Psychiatry Panel Receptors

Large-Scale Comprehensive Panels

Our large-scale panel assays allow comprehensive screening for up to 200 non-orphan GPCRs and 94 orphan GPCRs.

The total of 294 GPCRs amenable to panel assays are listed below.

Panel Assay Example

Figure 5. Carvedilol screened for 200 non-orphan GPCRs.

Figure 6. Concentration-response curves for carvedilol

Carvedilol, an anti-hypertensive agent, was screened in the antagonist mode for 200 non-orphan GPCRs (Figure 5). Carvedilol selectively antagonized α1A, α1B, α1D, β1, and β2 adrenoceptors. Next, carvedilol was shown to antagonize the above receptors in a concentration-dependent manner (Figure 6).

Panel Receptors

Listed are the total of 294 GPCRs amenable to panel assays and the GPCRs in the therapeutic area panels. Each panel is customizable.

Contact Us

Send us a message via the form below or write to us at [email protected].

Ordering Process

Service flow chart

Request a quotation

We hear about the study outline and propose experiments. A non-disclosure agreement is optional.


Place an order

You also ship your compounds to our lab and pay the fee via bank transfer.


Wait for a while

The turnaround time may be as short as two weeks but depends on the study scale and design and the backlog of orders.


Receive the report

We provide the study report via email.


Inquiry & RFQ Form